



# FINANCIAL TEAR SHEET


## CORPORATE PROFILE

At PRA Health Sciences, we work side-by-side with our clients, to move drug discovery forward, and to help them develop life-saving and life- improving drugs. For more than 30 years, we’ve been helping to bring to market everything from niche treatments and therapies to blockbuster drugs. Providing comprehensive Phase I-IV biopharmaceutical drug development in ove countries, we are dedicated to being innovative, and to delivering unmatched scientific expertise that improves the drug develop process.

We help change people’s lives for the better every single day. It’s what we are passionate about.

## STOCK QUOTE & CHART

PRAH (Common Stock)	
Exchange	NASDAQ GS (US Dollar)
Financial Status Indicator	C
Price	\$89.79
Change (%)	▼ 0.98 (1.08%)
Volume	92,662
52 Week Low	\$58.08
Market Cap	\$5,727,787,874
Rolling EPS	1.52
PE Ratio	59.6496
Shares Outstanding	63,790,933
Data as of 03/19/18 4:00 p.m. ET	



## NEWS & EVENTS

Date	Title
------	-------

There are currently no events scheduled.

03/14/18	PRA Health Sciences Receives CRO Leadership Award
03/06/18	PRA Health Sciences Named Best CRO in Asia
02/21/18	PRA Health Sciences, Inc. Reports Fourth Quarter and Full Year 2017 Results and Provides Q1 and FY 2018 Guidance

## SEC FILINGS

Filing Date	Form
02/22/18	10-K
02/21/18	8-K
02/14/18	SC 13G
02/13/18	SC 13G/A

## BOARD OF DIRECTORS

Colin Shannon	Chairman of the Board
Jeffrey T. Barber	Director
Alexander G. Dickinson	Director
Linda S. Graiss, M.D.	Director
Max C. Lin	Director
James C. Momtazee	Director
Ali J. Satvat	Director
Matthew P. Young	Director

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)